www.medical-devices.tech
17
'24
Written on Modified on
GE HealthCare News
GE HEALTHCARE FEATURES MOBILE MAMMOGRAPHY SCREENING TRUCK ALONG WITH LATEST AI PLATFORM
GE HealthCare featured its latest breast cancer detection technology during the 2024 Society of Breast Imaging Symposium in Montreal, Canada.
This year’s showcase featured the Mobile Mammography Screening Truck, the recently released MyBreastAI Suite and Pristina Bright.
GE HealthCare’s latest MyBreastAI Suite provides an all-in-one AI platform optimized for mammography to support clinicians with breast cancer detection. With this initial release, MyBreastAI Suite integrates three AI applications from iCAD including ProFound AI for DBT, SecondLook for 2D Mammography and PowerLook Density Assessment to help support early detection and improve patient outcomes, as well as help radiology departments improve operational productivity.
In an effort to help further advance breast cancer and support healthcare providers in starting a new contrast program, the company also showcased its Pristina Bright offering - a comprehensive solution that combines SenoBright HD, Pristina Serena, and Serena Bright with an education program that includes dedicated on-site support, CME accredited self-assessment, and access to a users’ club to share with experts around the globe and leverage resources needed to market their facility among referring doctors and patients.
With Pristina Bright, clinicians can see lesions that cannot be seen on routine mammography and biopsy what is seen within 15 minutes. To help improve overall productivity, Pristina Bright can also help providers take more patients on their system, with the ability to image up to 30 patients a day with contrast mammography through an easy-to-read exam.
GE HealthCare’s personalized breast cancer screening solutions include:
- Senographe Pristina, a mammography system designed to provide a better patient experience and optimized for rapid diagnosis;
- Invenia ABUS, the first FDA-approved automatic breast ultrasound supplemental screening specifically designed for detecting cancer in dense breast;
- SenoBright HD Contrast Enhanced Mammography (CEM), which combines mammography and vascular-based screening methods to highlight areas of unusual blood-flow patterns that may indicate malignancy - helping reduce the masking effect of fibro glandular breast tissue so lesions can be more clearly identifiable; and
- Serena Bright, the industry’s first contrast-guided biopsy solution which transforms the screening room into an interventional suite if medical indications recommend pathology.
